{"id":"genexol","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Genexol uses albumin-bound nanoparticle technology to solubilize paclitaxel without Cremophor EL, improving drug delivery to tumors and reducing hypersensitivity reactions. The nanoparticles preferentially accumulate in tumor tissue through the enhanced permeability and retention (EPR) effect, allowing higher intratumoral concentrations while maintaining a better tolerability profile compared to conventional paclitaxel formulations.","oneSentence":"Genexol is a paclitaxel-based nanoparticle formulation that delivers the chemotherapy agent to cancer cells while reducing systemic toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:58.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03618758","phase":"PHASE1, PHASE2","title":"Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-12-24","conditions":"Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel","enrollment":35},{"nctId":"NCT02739633","phase":"PHASE2","title":"Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas","status":"UNKNOWN","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2016-04","conditions":"Recurrent Adenocarcinoma of the Pancreas, Metastatic Adenocarcinoma of the Pancreas","enrollment":47},{"nctId":"NCT01276548","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2009-10","conditions":"Ovarian Cancer","enrollment":102},{"nctId":"NCT01023347","phase":"PHASE2","title":"A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2008-06","conditions":"Non Small Cell Lung Cancer","enrollment":276},{"nctId":"NCT00876486","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2008-12","conditions":"Breast Cancer","enrollment":213},{"nctId":"NCT02739529","phase":"PHASE1","title":"Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer","status":"UNKNOWN","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2016-04","conditions":"Gynecologic Cancer","enrollment":18},{"nctId":"NCT00877253","phase":"PHASE1","title":"Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2008-05","conditions":"Ovarian Cancer","enrollment":18},{"nctId":"NCT00912639","phase":"PHASE4","title":"A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer","status":"UNKNOWN","sponsor":"Korean Breast Cancer Study Group","startDate":"2009-05","conditions":"Recurrent Breast Cancer","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Genexol®","genericName":"Genexol®","companyName":"Samyang Biopharmaceuticals Corporation","companyId":"samyang-biopharmaceuticals-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Genexol is a paclitaxel-based nanoparticle formulation that delivers the chemotherapy agent to cancer cells while reducing systemic toxicity. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}